Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Juvenile Idiopathic Arthritis (JIA) Registry

A legfontosabb adatok

Ki végzi
AbbVie
Hol
Akron, Bismarck, Boston, Burlington, Chicago, Cincinnati, Columbus, Delray Beach, Durham, Ellicott City, Indianapolis, Kingsport, Little Rock, Los Angeles, Louisville, Memphis, Milwaukee, New Hyde Park, Omaha, Peoria, Philadelphia, Phoenix, Portland, Rochester, Round Rock, Salt Lake City, Seattle, Tucson, Valhalla, Washington D.C. és West Orange (Egyesült Államok)Mind a 32 helyszín megnézéseMég 16 másik országban, 60 helyszínen
Azonosító
Állapot
Befejeződött
Résztvevők
849 fő vett részt
Kezdés
2008. júl. 11.
Befejezés
2024. febr. 1.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • adalimumab
  • Methotrexate
A regiszteradat frissítve
2025. február 4.

Ki vehet részt

Életkor
2 év – 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • For a patient enrolling into the HUMIRA® arm; a pediatric patient diagnosed at any time with moderately to severely active polyarticular or polyarticular-course JIA (defined as arthritis affecting >= 5 joints at the time of diagnosis of polyarticular or polyarticular-course JIA) who has been prescribed HUMIRA® therapy according to the local approved HUMIRA® product labeling and meets one of the following criteria:
  • Enrolled patients are 4 to 17 years of age as per approved HUMIRA® product label with the addition of JIA patients 2 to < 4 years of age in countries with available local approval for this group of patients at the time of consent to the registry
  • Newly initiated (within 24 months of registry entry) on HUMIRA® therapy and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy, and the physician can provide available source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy
  • Or is entering after participation (within 24 months of registry entry or, if longer, continuously treated at the same site) in an AbbVie Humira sponsored study, regardless of age or the number of joints with symptoms of JIA, and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide available source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy
  • For a patient enrolling into the MTX arm; a pediatric patient diagnosed at any time with moderately to severely active polyarticular or polyarticular-course JIA (defined as arthritis affecting >= 5 joints at the time of diagnosis of polyarticular or polyarticular-course JIA) who is prescribed MTX therapy alone or in combination with other disease modifying anti-rheumatic drugs (DMARDs) according to the local product labeling (initiated treatment within 24 months of registry entry) and has received continuous therapy and the physician can available provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy
  • Patients who were treated in the MTX arm of this registry and prematurely discontinued from the MTX arm due to being a non-responder, or became intolerant of MTX treatment or are in need of combination treatment with HUMIRA® therapy may be eligible to enroll into the HUMIRA® treatment arm if all ongoing AEs/SAEs have been resolved, and they meet inclusion criteria and can enroll within the registry enrollment period. In case of ongoing AEs/SAEs at the time of the treatment arm switch, the AbbVie Designated Physician should be contacted to assess the eligibility of patient to roll into Humira treatment arm
  • Parent or guardian has voluntarily signed and dated an informed consent/patient authorization form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) if applicable according to local law, after the nature of the registry has been explained and the patient's parent or legal guardian has had the opportunity to ask questions. Pediatric patients will be included in all discussions as per applicable local regulations in order to obtain verbal or written assent

Ki nem vehet részt

  • Patients should not be enrolled into the HUMIRA® or MTX arm if they require on-going treatment with Kineret® (anakinra), Orencia® (abatacept), Rituxan® (rituximab), Enbrel® (etanercept), and Remicade® (infliximab), or any other approved biologic agents or investigational agents
  • Patients should not be enrolled into the MTX arm if they have had prior treatment with any investigational agent or anti-rheumatic biologic therapy such as, but not limited to, Orencia® (abatacept), Enbrel® (etanercept), Remicade® (infliximab), Rituxan® (rituximab), or Actemra® (tocilizumab)
  • Patients should not be enrolled into the HUMIRA® or Methotrexate (MTX) arm if they cannot be prescribed and treated in accordance with the approved local HUMIRA® and/or with the local MTX product label

Helyszínek itt: Egyesült Államok

Még 16 másik országban, 60 helyszínen

  • Akron Children's HospitalAkron, Egyesült Államok
  • Bone Spine Sports/Medctr OneBismarck, Egyesült Államok
  • Tufts Medical CenterBoston, Egyesült Államok
  • Children's Speciality CenterBurlington, Egyesült Államok
  • Ann & Robert H Lurie Children's Hospital of ChicagoChicago, Egyesült Államok
  • The University of Chicago Medical CenterChicago, Egyesült Államok
  • University of CincinnatiCincinnati, Egyesült Államok
  • Nationwide Children's HospitalColumbus, Egyesült Államok
  • Arthritis Associates South FLDelray Beach, Egyesült Államok
  • Duke Cancer CenterDurham, Egyesült Államok
  • Arthritis Care Spec. of MDEllicott City, Egyesült Államok
  • Indiana UniversityIndianapolis, Egyesült Államok
  • Arthritis Associates of KingsportKingsport, Egyesült Államok
  • Arkansas Children's HospitalLittle Rock, Egyesült Államok
  • Children's Hospital Los AngelesLos Angeles, Egyesült Államok
  • University of LouisvilleLouisville, Egyesült Államok
  • Dr. Ramesh GuptaMemphis, Egyesült Államok
  • Children's Hospital Wisconsin - Milwaukee CampusMilwaukee, Egyesült Államok
  • North Shore University HospitalNew Hyde Park, Egyesült Államok
  • Creighton Univ Med CtrOmaha, Egyesült Államok
  • Methodist Medical Group RheumPeoria, Egyesült Államok
  • St. Christopher's HospitalPhiladelphia, Egyesült Államok
  • AZ Arthritis and Rheumotology Research, PLLCPhoenix, Egyesült Államok
  • Legacy Emanuel Medical CenterPortland, Egyesült Államok
  • University of Rochester Medical CenterRochester, Egyesült Államok
  • Scott & White Health CareRound Rock, Egyesült Államok
  • University of UtahSalt Lake City, Egyesült Államok
  • Seattle Children's HospitalSeattle, Egyesült Államok
  • Catalina Pointe Clinical ResearchTucson, Egyesült Államok
  • New York Medical CollegeValhalla, Egyesült Államok
  • Children's National Medical CenterWashington D.C., Egyesült Államok
  • St. Barnabas Ambulatory CareWest Orange, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.

A vizsgálat 2 csoportja

  • HUMIRA® Treatment Arm

    For patients taking HUMIRA®

    Kezelés: adalimumab

  • Methotrexate Treatment Arm

    For patients taking Methotrexate

    Kezelés: Methotrexate

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE
A regiszteradat frissítve
2025. február 4.